The United Kingdom holds the position as the largest global exporter of medicinal cannabis. This reputation has been achieved as a result of the various companies within its borders receiving the necessary licenses to cultivate and export the drug for medical and scientific purposes. These companies have been sanctioned by the UK government to produce cannabis for medicinal and research uses, and they have been actively exporting these products to countries around the world where the use of medicinal cannabis is legal and widely accepted. Despite the UK’s commanding role in the global medicinal cannabis market, there is an interesting paradox within its domestic policy. The country itself does not allow for the prescription of medicinal cannabis that is produced domestically. This unusual circumstance arises from the strict and rigid regulations that have been set surrounding the use of cannabis-based medications within the UK’s healthcare system. These regulations, which are overseen by the Medicines and Healthcare products Regulatory Agency (MHRA), require that any new drug – including those based on cannabis – go through an extensive series of testing and clinical trials before it can be approved for prescription. This process is designed to ensure that every new medication is safe for use, effective in treating the condition it is intended for, and does not have unacceptable side effects. However, this rigorous approval process comes with a significant downside: it is highly costly and time-consuming. The need for extensive research and clinical trials means that it can take many years and millions of pounds before a new medication can be approved for use within the UK’s healthcare system. In the case of medicinal cannabis, this has created a scenario where it is often cheaper and faster for the UK to import medicinal cannabis from countries where it’s already been approved for medical use, rather than waiting for domestically produced cannabis to go through the UK’s approval process. This situation has led to a fascinating dichotomy in the UK’s relationship with medicinal cannabis. On one hand, the country is a global leader in the production and export of this potentially life-changing medication. On the other, it is also a country where patients cannot access domestically produced medicinal cannabis due to the stringent regulations in place. Despite this, the UK continues to play a pivotal role in the global medicinal cannabis industry, providing countries where it is legal with high-quality, rigorously tested products. And as the regulations and attitudes towards medicinal cannabis continue to evolve worldwide, the UK’s role in this industry is likely to remain significant and influential.